1887

Journal of Medical Microbiology logo

Volume 73, Issue 11

Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi No Access

Abstract

Mucormycosis is an aggressive, angioinvasive infection associated with high morbidity and mortality. The disease remains difficult to treat, with limited available antifungal drugs. Consequently, there is an urgent need to develop alternate therapeutics against mucormycosis. In an earlier study, we demonstrated that the non-steroidal anti-inflammatory drug diflunisal impacted the actin cytoskeleton and quorum sensing and inhibited the formation of filopodia-/cytoneme-like extensions in .

The non-steroidal anti-inflammatory drug diflunisal could exhibit potential antifungal activity.

This study aimed to investigate the plausible antifungal activity of diflunisal against a range of medically important and its combination effect with antifungal drugs.

The antifungal activity of diflunisal against , , and was evaluated by broth microdilution assay. Allied salicylates were also screened. A combination assay with amphotericin B deoxycholate and posaconazole was performed by fractional inhibitory concentration test.

Exposure to diflunisal inhibited spore germination in a dose-dependent manner. MICs of diflunisal against different ranged from 64 to 2048 µg ml. Remarkably low levels of diflunisal (0.03–2 µg ml), depending on the strain/species tested, improved the antifungal activity of amphotericin B against mucoralean fungi by twofold (ΣFIC ≈ 0.5–0.508; 0.01). Field-emission scanning electron micrographs further confirmed these observations. MICs of posaconazole were unchanged by this compound.

Considering that amphotericin B remains the first-line drug against mucormycosis and exhibits dose-dependent side effects in clinical practice, especially nephrotoxicity, the observed additive interaction at remarkably low, clinically achievable levels of diflunisal demonstrates its potential utility as an adjunct therapy against mucoralean fungi.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): amphotericin B , diflunisal , Mucor , mucormycosis and Rhizopus
Funding
This study was supported by the:
  • SERB Early Career Research Award (Award ECR/2016/000102)
    • Principle Award Recipient: RachnaSingh
  • Indian Council of Medical Research (Award 67/2/2020-DDI/BMS)
    • Principle Award Recipient: RachnaSingh
© 2024 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001929
2024-11-22
2024-12-08
Loading full text...

Full text loading...

References

  1. Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M et al. COVID-19-associated fungal infections. Nat Microbiol 2022; 7:1127–1140 [View Article] [PubMed]
     [Google Scholar]
  2. Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses 2014; 57 Suppl 3:85–90 [View Article] [PubMed]
     [Google Scholar]
  3. Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V et al. ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries. Mycoses 2021; 64:1028–1037 [View Article]
     [Google Scholar]
  4. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19:e405–e421 [View Article] [PubMed]
     [Google Scholar]
  5. Lamoth F, Kontoyiannis DP. Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients. Antimicrob Agents Chemother 2019; 63:e01244–01219 [View Article] [PubMed]
     [Google Scholar]
  6. Kaur M, Singh R. Volatile self-inhibitor of spore germination in pathogenic Mucorale Rhizopus arrhizus. FEMS Microbiol Ecol 2020; 96:fiaa170 [View Article] [PubMed]
     [Google Scholar]
  7. Kaur M, Kumari A, Singh R. The indigenous volatile inhibitor 2-methyl-2-butene impacts biofilm formation and interspecies interaction of the pathogenic Mucorale Rhizopus arrhizus. Microb Ecol 2022; 83:506–512 [View Article] [PubMed]
     [Google Scholar]
  8. Kraft R, Kahn A, Medina-Franco JL, Orlowski ML, Baynes C et al. A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions. Dis Model Mech 2013; 6:217–235 [View Article] [PubMed]
     [Google Scholar]
  9. Takeshita N, Manck R, Grün N, de Vega SH, Fischer R. Interdependence of the actin and the microtubule cytoskeleton during fungal growth. Curr Opin Microbiol 2014; 20:34–41 [View Article] [PubMed]
     [Google Scholar]
  10. Smethurst DGJ, Dawes IW, Gourlay CW. Actin - a biosensor that determines cell fate in yeasts. FEMS Yeast Res 2014; 14:89–95 [View Article] [PubMed]
     [Google Scholar]
  11. Clinical and laboratory standards institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. In CLSI Standard M38 (ISBN 1-56238-830-4 [Print]; ISBN 1-56238-831-2 [Electronic]), 3rd. edn Wayne, 321 Pennsylvania 19087 USA: Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500; 2500 p 950
     [Google Scholar]
  12. Singh R, Shivaprakash MR, Chakrabarti A. Biofilm formation by zygomycetes: quantification, structure and matrix composition. Microbiology 2011; 157:2611–2618 [View Article]
     [Google Scholar]
  13. Medwid RD, Grant DW. Germination of Rhizopus oligosporus Sporangiospores. Appl Environ Microbiol 1984; 48:1067–1071 [View Article] [PubMed]
     [Google Scholar]
  14. Clinical and Laboratory Standards Institute (CLSI) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. In CLSI Standard M27 (ISBN 1-56238-826-6 [Print]; ISBN 1-56238-827-4 ([Electronic]), 4th. edn Wayne, Pennsylvania 19087 USA: Clinical and Laboratory Standards Institute; 2500 p 950
     [Google Scholar]
  15. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antifungal susceptibility testing of filamentous fungi. In CLSI Supplement M61 (ISBN 978-1-68440-084-3 [Print]; ISBN 978-1-68440-085-0 ([Electronic]), 2nd. edn Wayne, Pennsylvania 19087 USA: Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500; 2020
     [Google Scholar]
  16. Singla P, Dalal P, Kaur M, Arya G, Nimesh S et al. Bile acid oligomers and their combination with antibiotics to combat bacterial infections. J Med Chem 2018; 61:10265–10275 [View Article] [PubMed]
     [Google Scholar]
  17. Kumari A, Mankotia S, Chaubey B, Luthra M, Singh R. Role of biofilm morphology, matrix content and surface hydrophobicity in the biofilm-forming capacity of various Candida species. J Med Microbiol 2018; 67:889–892 [View Article] [PubMed]
     [Google Scholar]
  18. Diflunisal Diflunisal tablets USP. Vaughan (ON): AA Pharma Inc; 2014 https://www.aapharma.ca/downloads/en/PIL/2016/Diflunisal-PM.pdf
  19. Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol 2012; 50:66–75 [View Article] [PubMed]
     [Google Scholar]
  20. Allende MC, Lee JW, Francis P, Garrett K, Dollenberg H et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38:518–522 [View Article] [PubMed]
     [Google Scholar]
  21. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528–534 [View Article] [PubMed]
     [Google Scholar]
  22. Khodaverdian V, Pesho M, Truitt B, Bollinger L, Patel P et al. Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57:3645–3652 [View Article] [PubMed]
     [Google Scholar]
  23. Pandey P, Verma V, Gautam G, Kumari N, Dhar SK et al. Targeting the β-clamp in Helicobacter pylori with FDA-approved drugs reveals micromolar inhibition by diflunisal. FEBS Lett 2017; 591:2311–2322 [View Article] [PubMed]
     [Google Scholar]
  24. Jayamani E, Tharmalingam N, Rajamuthiah R, Coleman JJ, Kim W et al. Characterization of a Francisella tularensis-Caenorhabditis elegans pathosystem for the evaluation of therapeutic compounds. Antimicrob Agents Chemother 2017; 61:e00310–00317 [View Article] [PubMed]
     [Google Scholar]
  25. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11:272–279 [View Article] [PubMed]
     [Google Scholar]
  26. Kong J, Zhang Y, Ju J, Xie Y, Guo Y et al. Antifungal effects of thymol and salicylic acid on cell membrane and mitochondria of Rhizopus stolonifer and their application in postharvest preservation of tomatoes. Food Chem 2019; 285:380–388 [View Article] [PubMed]
     [Google Scholar]
  27. Dalmont K, Biles CL, Konsure H, Dahal S, Rowsey T et al. Nonsteroidal Anti-inflammatory Drugs (NSAIDS) inhibit the growth and reproduction of Chaetomium globosum and other fungi associated with water-damaged buildings. Mycopathologia 2017; 182:1025–1036 [View Article] [PubMed]
     [Google Scholar]
  28. Zhang Q, Liu F, Zeng M, Mao Y, Song Z. Drug repurposing strategies in the development of potential antifungal agents. Appl Microbiol Biotechnol 2021; 105:5259–5279 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001929
Loading
Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi
J. Med. Microbiol. 73, 001929 (2024); https://doi.org/10.1099/jmm.0.001929
/content/journal/jmm/10.1099/jmm.0.001929
/content/journal/jmm/10.1099/jmm.0.001929
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error